Cambridge Trust’s Arbutus Biopharma ABUS Stock Holding History

Cambridge Trust’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$12.9K	Hold	5,000	–	–	﹤0.01%	560
2023 Q4	$12.5K	Hold	5,000	–	–	﹤0.01%	557
2023 Q3	$10.2K	Hold	5,000	–	–	﹤0.01%	579
2023 Q2	$11.5K	Hold	5,000	–	–	﹤0.01%	586
2023 Q1	$15.2K	Hold	5,000	–	–	﹤0.01%	587
2022 Q4	$12K	Hold	5,000	–	–	﹤0.01%	609
2022 Q3	$10K	Hold	5,000	–	–	﹤0.01%	639
2022 Q2	$14K	Hold	5,000	–	–	﹤0.01%	637
2022 Q1	$15K	Hold	5,000	–	–	﹤0.01%	697
2021 Q4	$19K	Buy	+5,000	New	+$19.4K	﹤0.01%	697

Other funds holding ABUS

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Trust's ABUS Position: Q1 2024 in Review

Cambridge Trust held its Arbutus Biopharma (ABUS) position steady in Q1 2024 at 5,000 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #560.

Cambridge Trust first reported a position in ABUS in Q4 2021 and has held it in 10 quarters since. The position peaked at $19K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

Cambridge Trust held 5,000 shares of Arbutus Biopharma worth $12.9K as of Q1 2024.
Cambridge Trust left its Arbutus Biopharma share count unchanged in Q1 2024.
Arbutus Biopharma made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #560 holding.
Cambridge Trust first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's Arbutus Biopharma position peaked at $19K in Q4 2021.
119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.